T1	Participants 94 141	patients with advanced head and neck carcinoma.
T2	Participants 354 443	patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma.
T3	Participants 444 597	Patients with locally advanced or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma not suitable for operation or radiotherapy
T4	Participants 730 798	One hundred and thirty-six eligible patients were randomly assigned.
T5	Participants 1566 1655	patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma.
